Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the schedule hereto:
Schedule
Product: Synercid
Active Ingredient(s): Dalfopristin 350mg
Quinupristin 150mg
Dosage Form: Powder for infusion
New Zealand Sponsor: Aventis Pharma Limited
Manufacturer(s): Catalytica Pharmaceuticals Inc, Greenville, North Carolina, United States of America
Note: This consent is valid for 2 years from the date of publication of this notice.
Dated this 14th day of June 2000.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).